Share Name Share Symbol Market Type Share ISIN Share Description
Ixico Plc LSE:IXI London Ordinary Share GB00BFXR4C20 ORD 1P
  Price Change % Change Share Price Shares Traded Last Trade
  1.00 1.48% 68.50 76,210 14:46:55
Bid Price Offer Price High Price Low Price Open Price
67.00 70.00 68.50 67.50 67.50
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 7.56 0.37 0.92 74.5 32
Last Trade Time Trade Type Trade Size Trade Price Currency
16:27:28 O 36,800 67.00 GBX

Ixico (IXI) Latest News

More Ixico News
Ixico Takeover Rumours

Ixico (IXI) Discussions and Chat

Ixico Forums and Chat

Date Time Title Posts
04/12/201915:55Ixico PLC134

Add a New Thread

Ixico (IXI) Most Recent Trades

No Trades
Trade Time Trade Price Trade Size Trade Value Trade Type
View all Ixico trades in real-time

Ixico (IXI) Top Chat Posts

Ixico Daily Update: Ixico Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker IXI. The last closing price for Ixico was 67.50p.
Ixico Plc has a 4 week average price of 65.50p and a 12 week average price of 45p.
The 1 year high share price is 77.50p while the 1 year low share price is currently 19p.
There are currently 46,777,000 shares in issue and the average daily traded volume is 211,543 shares. The market capitalisation of Ixico Plc is £32,042,245.
frreeves: and no share price reaction?
mirabeau: With a market capitalisation of £22m, Aim-traded IXICO (IXI:47p) may be under the radar of most investors, but the London-based company is at the forefront of a technological revolution. That’s because the world’s largest biopharmaceutical companies are investing huge sums of money in the field of neurology to target therapies for diseases affecting the central nervous system including Huntington’s, Alzeihmer’s and Parkinson’s disease. This has created a surge in demand for the services of companies that use proprietary artificial intelligence (AI) software algorithms to analyse images from brain scans - magnetic resonance imaging (MRI) and positron emission tomography (PET) – in order to provide measurements of small changes in brain structure, assess the efficacy of new drugs being trialled, monitor patient safety, and provide valuable insights on different aspects of trial performance. In a nut shell, IXICO’s cutting edge proprietary LEAP algorithm harnesses the power of large datasets and computer-based learning to segment specific regions of the brain and then accurately measure their volume, thus providing a reliable method of measuring brain atrophy which can indicate progression of neurological disease. To date the algorithm has been applied to over 150 brain regions, analysed over 100,000 brain scans and has been cited in over 750 scientific publications. The company has also developed AI technology to assess brain pathology like white matter lesions and, more recently, uses data from wearable biosensors to accurately measure sleep patterns in Parkinson’s disease and dementia patients. These approaches enhance the understanding of disease symptoms more directly compared to manual assessment or complex in-clinic technology. Importantly, by applying IXICO’s data science expertise, these measurements have the potential to increase success rates of clients’ clinical trials by improving patient selection, lowering the cost of running them, and reducing the burden on trial participants and their carers by reducing the need for clinic visits. High operational leverage The technology is proving incredibly popular. In fact, no fewer than eight of the 14 top 20 biopharmaceutical companies that have active neurological drug development programmes are clients of IXICO. They clearly hold the company in high esteem as IXICO has booked over £20m worth of new orders since the start of last year, a revenue stream that supports a sustained move to operating profitability. Once that inflexion point is passed, the high gross margin (62 per cent) earned from its cutting edge data analytics activities means that operating profits are set to move sharply higher in the years ahead given the significant amount of automation in the workflow and remote management of the clinical trial imaging sites. This means that IXICO is able to take on additional revenue generating activities without an equivalent increase in staffing costs, the effect of which is that any outperformance against revenue forecasts delivers a high conversion rate of incremental gross margin earned to operating profit. This operational leverage effect is also illustrated by the fact that over the past few years IXICO’s staffing levels have remained between 60 to 70 employees even though revenues earned have more than doubled since 2016. The possibility of profit upgrades was certainly not priced into the company’s valuation when I suggested buying IXICO’s shares, at 33p, in last month’s 8,000 word small-cap report for our Alpha subscribers ('Alpha: Simon Thompson spies opportunity in cutting edge technology', 23 July 2019). It still isn’t for that matter even after the 42 per cent rise in the company’s share price following yesterday’s trading update when management revealed that growth has been accelerated by new and existing contracts coming on line, deployment of newly developed algorithms and faster turnaround times in trial situations. Increased target price To put the current valuation into perspective, analyst Chris Donnellan at house broker Cenkos Securities has torn up his previous estimates and now expects IXICO to post 32 per cent revenue growth in the 2018/19 financial year, and 20 per cent top-line growth in both the 2019/20 and 2020/21 financial years, too. On this basis, IXICO’s annual pre-tax loss is forecast to be slashed from £0.8m to £0.1m on revenue up from £5.4m to £7.1m in the 12 months to 30 September 2019. Furthermore, Mr Donnellan now forecasts that IXICO will generate both an operating and pre-tax profit of £239,000 on revenue of £8.5m in the 2019/20 financial year to produce a net profit of £339,000, rising to an operating and pre-tax profit of £0.88m, and net profit of £0.79m on revenue of £10.25m in the 2020/21 financial year. He had previously forecast a £0.44m operating profit on revenues of £9.55m in the 2020/21 financial year, so the additional £0.7m of revenue that is now expected to be booked that year will produce £0.43m of incremental gross margin, all of which is effectively being converted into operating profit. Cenkos estimate IXICO will have net funds of £5.5m at the end of next month which means that its enterprise valuation of £16.5m equates to 20 times forecast net profits in the 2020/21 financial year, hardly a punchy rating for a highly operationally geared business that is winning new orders and looks to be at the start of an earnings upgrade cycle. Indeed, around two-thirds of the 2020 revenue target is already covered by the contracted order book, so if contract momentum continues to build then it’s not unrealistic to expect IXICO to over deliver even against analysts’ upgraded expectations. In the circumstances, I am raising my 55p target price to 62p, implying a fair value enterprise valuation of £23.5m, in anticipation of the contract momentum in the business continuing to build and the release of another positive pre-close trading update in mid-October. Trading on a bid-offer spread of 45p to 47p, I continue to rate IXICO’s shares a buy.
jpuff: Great news, but never seems to lift the share price alas.
jondev: Has the share price gone down because they spent 2.7 million buying some random company with no consultation from shareholders???
geoff80: LSE:IXI OKSearch Ixico Share News (IXI) 5 Follow IXI Share Name Share Symbol Market Type Share ISIN Share Description Ixico LSE:IXI London Ordinary Share GB00BCLY7L40 ORD 1P Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade +0.50p +2.04% 25.00p 24.00p 26.00p 25.00p 24.50p 24.50p 7,318 10:06:15 Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m) Pharmaceuticals & Biotechnology 3.1 -1.4 -7.9 - 6.62 Print Alert IXICO plc Participation in major EU partnership (ROADMAP) 16/11/2016 7:00am UK Regulatory (RNS & others) IXICO plc 16 November 2016 16(th) November 2016 IXICO plc ("IXICO" or the "Company") IXICO to receive EUR100k funding to provide digital technologies for collection and analysis of data in a "real world" setting Further expansion of work on wearable bio-sensors as part of a major EU public-private partnership (ROADMAP) IXICO, the brain health company, today announces its participation in a new collaborative pan-European research effort under the Innovative Medicines Initiative's (IMI) umbrella focused on addressing the challenges of successfully delivering therapies to people with Alzheimer's disease (AD). In this collaboration with leading pharmaceutical companies and academics, IXICO is receiving EUR100k of funding to undertake data aggregation and analysis using its digital technology platforms. The platforms will be used to devise clinically meaningful measurements from biosensors worn by patients, and to develop enhanced models of disease progression to help select the most appropriate treatment for an individual patient. Within ROADMAP, IXICO will demonstrate how both approaches can be deployed in real-world settings, leveraging IXICO's existing activities in the Cygnus real world evidence (RWE) study (hxxp:// Derek Hill, CEO of IXICO, said: "IXICO is delighted to be joining the ROADMAP consortium. It provides an excellent opportunity for us to advance our capabilities in wearable biosensors and digital disease models, working collaboratively with leading pharmaceutical companies and academics. These are key technologies that are likely to accelerate the approval of and access to beneficial treatments for AD, and we believe they will provide commercial growth opportunities for IXICO." This project will enhance capabilities currently integrated into IXICO's TrialTracker(TM) and Assessa(R) digital health platforms, which are used by pharmaceutical companies both to support development of new treatments and used alongside marketed drugs. This innovative collaboration brings together 22 leading academic, healthcare and pharmaceutical partners, including Novartis Pharma AG, Eli Lilly and Company Ltd, Biogen, F. Hoffman-La Roche Ltd, Janssen Pharmaceutica NV, GE Healthcare Ltd and AC Immune SA. ROADMAP is also looking to identify which combinations of clinical tests and biomarkers support accurate diagnosis and prognosis of disease in asymptomatic patient populations in Alzheimer's disease. For further information please contact: IXICO plc Derek Hill, Chief Executive Officer Tel: +44 20 Susan Lowther, Chief Financial Officer 3763 7499 Shore Capital (Nomad and Broker) Tel: +44 20 Bidhi Bhoma / Edward Mansfield 7408 4090 FTI Consulting Limited (Investor Tel: +44 20 Relations) 3727 1000 Simon Conway/Mo Noonan/Matthew Moss About IXICO IXICO's innovative and proprietary digital healthcare technologies help those involved in researching and treating serious diseases to capture and analyse clinical data to make rapid, informed decisions. In clinical research this includes the phenotyping of patients, quantification of disease pathology and measurement of patient outcomes. In clinical practice the mobile health and digital decision support technologies aid diagnosis, patient engagement and monitoring. IXICO is also collaborating with partners to develop companion digital health products targeted at improving patient outcomes. The Company's brain health focus includes Alzheimer's disease, Huntington's disease, multiple sclerosis, Parkinson's disease, behavioural health, child and adolescent mental health. More information is available on About ROADMAP ROADMAP aims to provide the foundation for a much-needed integrated data environment and framework for Real World Evidence (RWE) in AD including: -- The development of consensual key outcome measures across stakeholder groups; -- Enabling data integration tools for dataset characterisation and outcome classification, data standards, data sourcing, software application repository; -- Guidelines on the handling and interpretation of RWE data. In addition, the following priorities have been identified: -- Outcome measurement; -- Identifying the best natural history model; -- Identifying the best pharmacoeconomic modelling strategy; -- Using short-term data to model long-term effects; -- Using short-term data to model long-term economic impact; -- Association between cognition, QoL (quality of life) and function over the AD spectrum; -- Identifying combination markers for diagnosis in asymptomatic patient population; -- Identifying combination markers for prognosis. ROADMAP is mainly sponsored by the European Union's Horizon 2020 research and innovation programme and the European pharmaceutical industry (via EFPIA) under the auspices of the Innovative Medicines Initiative 2 Joint Undertaking. The ROADMAP programme has budget of EUR7.77M distributed across a total of 22 partners from the private and academic sectors: * The University of Oxford * London School of Economics and Political Science * National Institute for Health and Care Excellence * Agentschap College ter Beoordeling van Geneesmiddelen * Erasmus Universitair Medisch Centrum Rotterdam * IXICO Technologies Ltd * Universiteit Maastricht * Rijksuniversiteit Groningen * Synapse Research Management Partners S.L. * Novartis Pharma AG (Project Leader) * Fundació Institut Universitari per la Recerca a * Eli Lilly and Company Ltd l'Atenció Primària de Salut Jordi Gol i Gurina * Biogen * Københavns Universitet * F. Hoffman-La Roche Ltd * Alzheimer Europe * Janssen Pharmaceutica NV * The University of Edinburgh * GE Healthcare Ltd * Goeteborgs Universitet * AC Immune SA * Aarhus Universitet About the Innovative Medicines Initiative The Innovative Medicines Initiative (IMI) is Europe's largest public-private initiative aiming to speed up the development of better and safer medicines for patients. IMI supports collaborative research projects and builds networks of industrial and academic experts in order to boost pharmaceutical innovation in Europe. IMI is a joint undertaking between the European Union and the European Federation of Pharmaceutical Industries and Associations, EFPIA. More information can be found at Acknowledgement The project leading to this application has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 116020. This
loobrush: Well not many seem interested in this share at the moment but as a healthcare share and in dementia they should be. Clearly undervalued, I expect that an analyst will pick this up soon, maybe when results out. Directors recently awarded options. The award of options under the Scheme are over the ordinary shares in the Company and are exercisable at an exercise price of 49.0p subject to various conditions. For each Executive Director, half of the options will not vest earlier than one year from the date of grant and will be subject to absolute share price performance. The options will vest in equal tranches on the first, second the third anniversary of grant with an annual hurdle of 10% share price appreciation being required in any 12 month period. The other half of the options are subject to a number of enhanced performance criteria including a more than doubling of the share price in a twelve month period or other corporate and strategic goals being met. So Directors have options which are only exercisable if share price goes up and minimum level to get some is 49p+10% = 54p -that's 35% above today's price. Also some of the options subject to DOUBLING SHARE PRICE That's a big incentive to get the company really moving.
loobrush: lse board Ixico has dropped to a low for the year at 35p and in my view is due for a big bounce. The company is one of two on the market involved in Dementia diagnosis and has recently launched a dimentia diagnostic kit which it is promoting. With the immense focus on this disease by the government this could turn into really big business Directors were recently granted options at 49p with the ability to take these up subject to increasing the share price from 49p. The company has been doing very well lately too. An update is due from the company in December Cash in the bank of over £3 million and company valued at only £5.25 million inc cash this has got to be a steal. Was as high as 120p has dropped a lot.
loobrush: I think you may be wrong in your assumption that its not worth chasing ,as you have pointed out with only a few shares being traded this exagerates the price movement, both up and down. However most investors have not cottoned on to what this company actually does and what the potential is. A visit to the IXICO website explains this in some detail and is very worthwhile, however this does not provide any financial projections of the three areas of their business. I am advised that this will be forthcoming in the new year. However, waiting until this is available or the company is anylised in the press or elsewhere may be unwise as the share price will take off again on any positive comment and you may miss the boat.
loobrush: from coldascheese on iii board "Researching more into and dementia and the other brain problems that there are I have only just understood how really big the problem is and what this will mean for IXICO. According to article in the Daily mail today(10 December) page 51, 25 billion has been spent on research into cures and treatments of DEMENTIA and ALZHEIMER'S and the amount is going to increase dramatically. Tomorrow sees the start of the G8 summit in London on this problem where all the experts from the worlds leading economies will meet to coordinate an action plan for tackling this. Professor Hill the chief exec of IXICO who recently signed the deal with the Chinese Academy of Medical Science will be in attendance. Tonight on NEWSNIGHT this summit meeting and the action required from it was discussed in more detail with the minister responsible advising that a great deal t more money was going to be spent on research into this problem. With Professor Hill and his team at IXICO being the only quoted company in this field and WORLD LEADERS at what the do in research IXICO will receive much greater publicity than of late and show what a truly great opportunity exists with this company and share price. They are already earning money and have over 8 million in the bank so are not like your usual cash hungry research/medical companies on multiple pe ratios valued at ten times the amount. I would also remind all about the company from their recent Aim Listing IXICO brings innovative technologies to those researching, diagnosing and treating serious diseases, especially dementia. Its technologies enable timely decision-making aimed at improving patient outcomes. IXICO was founded with a mission to translate image acquisition, management and analysis technology and know-how, which the founders had developed together, into commercial products. These target the expanding area of imaging to inform decision-making during drug development, especially for treatments for Alzheimer's Disease and other brain disorders. This has resulted in commercially successful products being launched in the clinical trials and experimental medicine markets and such products are now being readied for launch into the wider clinical diagnostic market to support the diagnosis of dementia Products ready for launch it says. Small holding PI's who have not understood the potential here have been selling today I would advise them to do bit more research as the potential of the company and what could come from this summit to the benefit of IXICO will be truly dramatic. The Chinese have recognized it-this share will be many multiples of todays price in a years time. " THIS HAS GOT TO BE AN OUSTANDING BUY AND I AM ADDING TO MY HOLDING
Ixico share price data is direct from the London Stock Exchange
Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20191209 04:53:58